GCM
IONS icon

Ghisallo Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Ghisallo Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$3.5M – 130
2024
Q4 		$3.5M Sell
100,000
-300,000
-75% -$11.2M 0.2% 82
2024
Q3 		$16M Buy
+400,000
New +$18.6M 0.79% 31

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ghisallo Capital Management's IONS Position: Q1 2025 in Review

Ghisallo Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 100,000 shares — an estimated $3.5M sold.

Ghisallo Capital Management first reported a position in IONS in Q3 2024 and held it in 2 quarters. The position peaked at $16M in Q3 2024. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

  • Ghisallo Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ghisallo Capital Management sold 100,000 Ionis Pharmaceuticals shares in Q1 2025, an estimated $3.5M.
  • Ghisallo Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Ghisallo Capital Management's Ionis Pharmaceuticals position peaked at $16M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Ghisallo Capital Management's 13F filing for Q1 2025, filed 15 May 2025.